Ensysce Biosciences Q3 EPS $(0.87) Beats $(1.06) Estimate, Sales $435.38K Miss $590.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) reported Q3 losses of $(0.87) per share, beating the analyst consensus estimate of $(1.06) by 17.92%. However, the company's quarterly sales of $435.38K missed the analyst consensus estimate of $590.00K by 26.21%. Despite the miss, this is a 55.85% increase over sales of $279.35K from the same period last year.
November 09, 2023 | 10:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ensysce Biosciences reported better than expected Q3 EPS but missed on sales. This mixed result could lead to volatility in the stock's price.
Ensysce Biosciences reported a better than expected EPS, indicating improved profitability. However, the company missed on sales, which could be a concern for investors as it indicates lower than expected revenue. This mixed result could lead to volatility in the stock's price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100